Reduction in Th-POK gene dosage results in increased NKT17 cells in the peripheral LN. (A) Plots depict representative staining of electronically gated CD19⁻ peripheral LN cells from Th-POK^hd/hd, Th-POK^hd/+, and Th-POK^+/+ mice with αGalCer-CD1d tetramers and anti-TCRβ mAbs. (B) Scatter plots depict the percentages of Vα14i NKT cells of total cells recovered from the peripheral LN of littermate or age-matched sets of Th-POK^hd/hd, Th-POK^hd/+ and Th-POK^+/+ mice (n = 8). Each set of mice is represented by a unique symbol. P values were determined by paired Student t tests. (C) Plots depict staining of LN Vα14i NKT cells from Th-POK^hd/hd, Th-POK^hd/+, and Th-POK^+/+ age-matched mice with antibodies against CD196 and CD103 (top row) or RORγT and NK1.1 (bottom row). Data are representative of 6 separate experiments. (D) Plots depict IL-17 and RORγT expression in electronically gated peripheral LN Vα14i NKT cells from Th-POK^+/+, Th-POK^hd/+, and Th-POK^hd/hd mice that were challenged with 2 μg of αGalCer, as well as a Th-POK^+/+ mock-injected animal. Mice were injected 2.5 hours before harvesting of organs. Data are representative of 2 separate experiments.